We searched PubMed for articles published in English between Jan 1, 2005, and Feb 27, 2013, and Summon Search between Jan 1, 2005, and Feb 27, 2013, with the search terms “systemic lupus erythematosus” and “lupus” in combination with the terms “management” and “biologics”. We also searched the references of articles identified by this strategy and selected those that were relevant.
SeriesSystemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment
Introduction
The prognosis of patients with autoimmune rheumatic diseases has improved substantially. In the 1950s, the 4 year survival for patients with systemic lupus erythematosus was 50%, now 15 year survival is 85%.1 In this part of the Series on autoimmune rheumatic diseases, we briefly review the treatment of these disorders, focusing mainly on systemic lupus erythematosus, and highlight the recent advances that have been made in biological treatments.
Section snippets
Pharmacological management
The mechanisms of action and indications for the drugs used to treat autoimmune rheumatic diseases are diverse. The table summarises the commonly prescribed conventional drugs available for the treatment of systemic lupus erythematosus. The main advances in the past decade in the conventional management of systemic lupus erythematosus have included studies showing efficacy for mycophenolate as an induction agent for lupus nephritis7, 10 and the equivalent efficacy of low-dose cyclophosphamide
New biological treatments
Improved understanding of the immune response and abnormalities in apoptosis have allowed the recognition of cells and molecules that are crucial to the development of systemic lupus erythematosus and other autoimmune rheumatic diseases. Increased recognition of the multifaceted role that B cells have in the pathophysiology of systemic lupus erythematosus has led to the development of several novel treatments, notably rituximab and belimumab. The failure of some other agents targeted at
Controversies about the use of biological agents for autoimmune rheumatic diseases
By contrast with the highly successful introduction of biological drugs for the treatment of rheumatoid arthritis, the use of these drugs in systemic lupus erythematosus, Sjögren's syndrome, myositis, and vasculitis has remained more problematic. Some notable successes of clinical trials have been belimumab in systemic lupus erythematosus and rituximab in antineutrophil cytoplasmic antibody-positive vasculitis; however, several frustrating failures have also been reported including the use of
Conclusions
We are at a challenging crossroads with regards to the treatment of autoimmune rheumatic diseases. The limit of what conventional drugs can achieve has probably been reached. Improved understanding of the aetiopathogenesis of these diseases with the introduction of more targeted biological treatment is beginning to show some encouraging signs of improvement in the outlook for these patients. However, this improvement is still lagging behind what has been achieved in the past decade for
Search strategy and selection criteria
References (92)
- et al.
Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts
Autoimmun Rev
(2012) - et al.
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Lancet
(2011) - et al.
Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis
J Pediatr
(2012) - et al.
Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase
Clin Immunol
(2005) - et al.
Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression
J Autoimmun
(2009) - et al.
Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients
Hum Pathol
(1995) - et al.
Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial
Lancet
(2011) - et al.
Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years
J Rheumatol
(1997) - et al.
Accrual of organ damage over time in patients with systemic lupus erythematosus
J Rheumatol
(2003) Antimalarial therapies
Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus
J Exp Med
Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review
Ann Rheum Dis
Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial
Ann Rheum Dis
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis
J Am Soc Nephrol
Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study
Rheumatology (Oxford)
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
N Engl J Med
The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide
Ann Rheum Dis
Pathogenesis of systemic lupus erythematosus
J Clin Pathol
Long-lived autoreactive plasma cells drive persistent autoimmune inflammation
Nat Rev Rheumatol
Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus—a prospective pilot study
Rheumatology (Oxford)
Rituximab and lupus interstitial lung disease: friend or foe?
Int J Rheum Dis
Successful treatment of recurrent pancreatitis secondary to systemic lupus erythematosus with B-cell depletion therapy
Arch Iran Med
Colitis associated with active systemic lupus erythematosus successfully treated with rituximab
J Clin Rheumatol
Successful rituximab therapy in a lupus patient with diffuse alveolar haemorrhage
Lupus
Rituximab in the treatment of bullous systemic lupus erythematosus
J Clin Rheumatol
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial
Arthritis Rheum
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study
Arthritis Rheum
Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus
Lupus
Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome
Clin J Am Soc Nephrol
Six refractory lupus patients treated with rituximab: a case series
Arthritis Rheum
B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus
Arch Dis Child
Multicenter retrospective analysis of the effectiveness and safety of rituximab in Korean patients with refractory systemic lupus erythematosus
Autoimmune Dis
Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study
Lupus
Off-label use of rituximab in systemic lupus erythematosus: a systematic review
Clin Rheumatol
Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids
Nephrol Dial Transplant
Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen
Rheumatology (Oxford)
Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?
Rheumatology (Oxford)
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis
Arthritis Care Res (Hoboken)
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
Ann Rheum Dis
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
Ann Rheum Dis
Rituximab versus cyclophosphamide for ANCA-associated vasculitis
N Engl J Med
Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial
Arthritis Rheum
Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study
Ann Rheum Dis
Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial
Arthritis Rheum
Efficacy of rituximab in primary Sjögren's syndrome with peripheral nervous system involvement: results from the AIR registry
Ann Rheum Dis
Cited by (97)
The interplay between mitochondrial dynamics and autophagy: From a key homeostatic mechanism to a driver of pathology
2024, Seminars in Cell and Developmental BiologyAutoimmune rheumatic disease in Australian Aboriginal and Torres Strait Islander Peoples: What do we know?
2024, Seminars in Arthritis and RheumatismDysregulated balance in Th17/Treg axis of Pristane-induced lupus mouse model, are mesenchymal stem cells therapeutic?
2023, International ImmunopharmacologyThe global burden of heterogeneity of lupus erythematosus interventional trials
2022, Journal of AutoimmunityJieduquyuziyin Prescription alleviates hepatic gluconeogenesis via PI3K/Akt/PGC-1α pathway in glucocorticoid-induced MRL/lpr mice
2022, Journal of EthnopharmacologyAgreement between biopsy and renal function in paediatric patients with lupus nephritis. A retrospective study
2021, Revista Colombiana de Reumatologia